A Phase 1, Open-Label, Multicenter Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IO-108 as Monotherapy and in Combination With Anti-PD-1 Monoclonal Antibody in Adult Patients With Advanced or Metastatic Solid Tumors
Latest Information Update: 28 May 2024
At a glance
- Drugs IO-108 (Primary) ; Pembrolizumab (Primary) ; Tislelizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immune-Onc Therapeutics
Most Recent Events
- 23 May 2024 Status changed from recruiting to completed.
- 07 Oct 2022 Status changed from not yet recruiting to recruiting.
- 18 Aug 2022 Status changed from planning to not yet recruiting.